The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma. by Showalter, Timothy N et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Surgery Faculty Papers Department of Surgery
8-1-2012
The influence of prognostic factors and adjuvant
chemoradiation on survival after
pancreaticoduodenectomy for ampullary
carcinoma.
Timothy N Showalter
Thomas Jefferson University
Tingting Zhan
Thomas Jefferson University
P Rani Anne
Thomas Jefferson University
Inna Chervoneva
Thomas Jefferson University
Edith P Mitchell
Thomas Jefferson University
See next page for additional authorsLet us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/surgeryfp
Part of the Surgery Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Surgery Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Showalter, Timothy N; Zhan, Tingting; Anne, P Rani; Chervoneva, Inna; Mitchell, Edith P; Yeo,
Charles J; Rosato, Ernest L; Kennedy, Eugene P; and Berger, Adam C, "The influence of prognostic
factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary
carcinoma." (2012). Department of Surgery Faculty Papers. Paper 42.
http://jdc.jefferson.edu/surgeryfp/42
Authors
Timothy N Showalter, Tingting Zhan, P Rani Anne, Inna Chervoneva, Edith P Mitchell, Charles J Yeo, Ernest
L Rosato, Eugene P Kennedy, and Adam C Berger
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/surgeryfp/42
As submitted to:  
Journal of Gastrointestinal Surgery 
 
And Later published as: 
 
The influence of prognostic factors and adjuvant 
chemoradiation on survival after 
pancreaticoduodenectomy for ampullary carcinoma 
Volume 15, Issue 8, August 2011, Pages 1411-1416 
DOI: 10.1007/s11605-011-1518-6 
 
Timothy N. Showalter1, Tingting Zhan2, P. Rani Anne1, Inna Chervoneva2, Edith P. 
Mitchell3, Charles J. Yeo4, Ernest L. Rosato4, Eugene P. Kennedy4, Adam C. Berger4 
 
1Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson 
University, Kimmel Cancer Center, Philadelphia, PA; 2 Division of Biostatistics, 
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson 
University, Philadelphia, PA; 3 Department of Medical Oncology, Jefferson Medical 
College of Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, PA;4 
Department of Surgery, Jefferson Medical College of Thomas Jefferson University, and 
the Jefferson Pancreas, Biliary and Related Cancer Center, Philadelphia, PA 
 
Correspondence: Adam C. Berger; 1100 Walnut Street, MOB, Suite 500; Philadelphia, 
PA 19147; phone—(215) 955-1622; fax—(215) 923-8222; email: 
adam.berger@jefferson.edu 
 
This work was originally presented in poster form at the Fifth ASCO GI Symposium, 
January 2009 (Orlando, FL). 
 
Running Title: Ampullary cancer prognostic factors 
Key Words: ampullary cancer, adjuvant therapy, ampulla of Vater, adenocarcinoma 
 
 
 
 
ABSTRACT 
INTRODUCTION:  The prognosis after pancreaticoduodenectomy (PD) for ampullary 
carcinoma (AC) is superior to that of pancreatic cancer.  Decisions regarding adjuvant 
therapy are influenced by factors such as nodal status, stage, and grade, but the influence 
of these individual variables on survival is unclear.   
METHODS:  A prospective tumor registry database was queried to identify patients who 
underwent PD for AC at Thomas Jefferson University between 1/1997 and 4/2009.  The 
study was conducted with the approval of the institutional review board.  Data were 
collected through review of hospital and departmental charts.  Overall survival (OS) was 
analyzed using univariate and multivariate Cox proportional hazard models. The 
proportional hazard assumption was verified for the overall model and individual 
covariates. 
RESULTS:  A total of 61 patients underwent PD for AC at our institution.  There were 5 
peri-operative deaths (8.2%).  Mean age was 70 years (62% male).  Median survival time 
(MST) was 50 months for all patients.  Only primary tumor stage, T1/T2 versus T3/T4 
(American Joint Committee on Cancer Staging Version 6), was associated with OS in 
univariate analyses (p = 0.003).  The association of nodal status with OS was borderline-
significant (p = 0.08), with the MST being 84 months for node-negative and 17 months 
for node-positive patients.  The remaining covariates were not predictors of OS.  In the 
multivariate analysis, only primary tumor stage (HR 5.1, p < 0.001) and age (HR 1.04, 
p=0.06), but not nodal status or adjuvant therapy, were associated with overall survival. 
CONCLUSIONS:  Advanced primary tumor stage and age were associated with inferior 
OS after PD for AC.  Adjuvant therapy did not impact survival.  Patients with advanced 
tumor stage should be considered for clinical trials of adjuvant therapy after PD with 
novel compounds and optimized radiation therapy strategies. 
INTRODUCTION 
 Carcinoma of the ampulla of Vater is a relatively uncommon malignancy and 
accounts for approximately 10 to 20% of pancreaticoduodenectomies (PDs) performed 
for periampullary cancers 1-3.  Prognosis after PD for ampullary carcinoma (AC) is 
superior to that of pancreatic cancer (PC), with higher rates of complete surgical 
resection, lower recurrence rates, and longer survival 1.  Published 5-year overall survival 
(OS) rates for ampullary carcinoma range from 38% to 68% 1-7.  There are less published 
data available for AC than for PC to assist with decisions regarding adjuvant therapy.  
The only randomized, prospective trial of adjuvant radiotherapy and concurrent 
chemotherapy to include patients with AC was that reported by the European 
Organisation for Research and Treatment of Cancer (EORTC) 8.  This study randomized 
patients with cancers of the pancreatic head or the periampullary region, defined as the 
distal common bile duct, ampulla of Vater, or duodenum, to the addition of adjuvant 
chemoradiotherapy (CRT) after surgery versus surgery alone.  The study results showed 
that CRT did not improve OS rates in this trial.  Results of this study are controversial, 
but they do not lend support for adjuvant therapy for either PC or AC 8.  Retrospective, 
single-institution studies have suggested conflicting results for the role of CRT in AC; 
most notably that adjuvant CRT extends survival either only in patients with involved 
lymph nodes,5 or only in patients with advanced tumor stage.9      
 Previous retrospective studies have identified clinical and pathologic factors that 
predict poorer outcome after PD for AC, in an effort to identify high-risk patients who 
may benefit most from adjuvant therapy.  Reported prognostic factors include specimen 
lymph node involvement, poor histologic grade, positive resection margins, and higher 
tumor stage (T3/T4 versus T1/T2).1,3,5,7,10,11 This analysis of outcomes for patients treated 
for AC at Thomas Jefferson University Hospital was performed to evaluate the 
associations of reported prognostic factors with overall survival after PD, and to assess 
the impact of adjuvant CRT on overall survival.   
METHODS 
 A prospective tumor registry database was queried to identify patients who 
underwent PD for AC at Thomas Jefferson University between 1/1997 and 4/2009.  The 
study was conducted with the approval of the institutional review board.  Data were 
collected through chart review and included age, gender, perioperative complications, 
margin status, stage, adjuvant therapy, survival, and recurrence.  Tumor staging was 
performed according to the 7th edition of the American Joint Committee on Cancer 
Staging Manual (Tables 1 and 2).  During the study period, decisions regarding adjuvant 
therapy were made by the treating physicians without a consistent policy, but the 
tendency was to reserve CRT for those patients with high-risk features such as positive 
nodes.     
 Time to recurrence (TTR) was estimated from the date of surgical resection, and 
the location of first recurrence was recorded.  The recurrence rate for node-positive 
tumors was compared to node-negative tumors using Fisher exact test.  Overall survival 
(OS) was estimated from the date of surgical resection.  The overall survival was 
analyzed using univariate and multivariate Cox proportional hazard models and reported 
including 95% confidence intervals (CI).  For statistical analysis, tumor (T) stage was 
dichotomized as “low” (T1/T2) versus “high” (T3/T4), and the histological grade was 
dichotomized as “low” (well- and moderately-differentiated) versus “high” (poorly-
differentiated).  Factors included in the multivariate analysis were age, primary tumor 
stage (T1/T2 vs. T3/T4), grade, nodal status (N0 vs. N1), adjuvant CRT and adjuvant 
chemotherapy.  The final multivariate Cox model was selected using the Akaike 
Information Criterion.12 The proportional hazard assumption was verified for the overall 
model and for the individual covariates.  Data were analyzed in R 2.10 (R Foundation for 
Statistical Computing, http://www.R-project.org). 
RESULTS 
 Sixty-one patients were identified who underwent PD for AC at our institution 
between 1/1997 and 4/2009.  There were 5 peri-operative deaths (8.2%), with the causes 
being pulmonary embolism in 1 patient, respiratory failure in 1 patient, and cardiac 
events in 3 patients.  Median follow-up of surviving patients was 22.4 months.  Average 
age was 70 years, and 62% were male.  Negative microscopic margins (R0) were 
achieved in 58 patients (95%).  Positive margins (n=3) were identified at the uncinate 
(n=1) and circumferential (n=2) margins of resection.  Sixteen patients (29%) received 
adjuvant RT, which was delivered in combination with concurrent 5-fluorouracil (5-FU) 
or capecitabine.  RT doses used were 45-52.2 Gy, with median of 50.4 Gy.  Five patients 
treated with adjuvant CRT also received intraoperative RT boost (median dose, 15 Gy).  
A total of 25 patients received additional adjuvant chemotherapy after CRT, including 
gemcitabine or 5-FU (Table 3).   
Recurrence 
 Tumor recurrence was observed in 20 patients (36%) at a median of 10.5 months 
after surgery.  Distant metastases were present at the time of first recurrence in 13 
patients, including liver in 11 patients and lungs in 3 patients.  Regional lymph nodes 
were involved at time of first recurrence for 6 patients.  Initial recurrence of AC was 
noted to be locoregional-only, without any distant dissemination, for 4 patients.  Three of 
20 (15%) node-negative patients developed recurrence, which occurred in regional lymph 
nodes (n=1) and liver (n=2).  Seventeen of 41 (41%) node-positive patients developed 
recurrence, which occurred in regional lymph nodes (n=5), liver (n=9), and lungs (n=3).  
The recurrence rate for node-negative patients was significantly lower than for node-
positive patients (p = 0.03). 
Survival 
 The median survival time (MST) was 50 months for all patients, with 2-year and 
5-year survival rates of 64% (95% CI, 52%-80%) and 44% (95% CI, 30%-65%), 
respectively (Figure 1).  The 2-year and 5-year survival rates were 85% (95% CI, 73%-
100%), and 65% (95% CI, 46%-92%), respectively, for T1/T2 tumors (n=33), versus 
39% (95% CI, 23%-67%), and 20% (95% CI, 6%-60%) for T3/T4 tumors (n=28) (p = 
0.003).  The MST was not reached for the T1/T2 group, and was 16 months for the T3/T4 
group (Figure 2).  The MST, 2-year survival and 5-year survival rates were 84 months, 
85% (95% CI, 71%-100%), and 60% (95% CI, 38%-94%), respectively, for node-
negative tumors, versus 17 months, 50% (95% CI, 34%-72%) and 33% (95% CI, 17%-
65%) for node-positive tumors (Figure 3) (p = 0.081).  As concerns overall survival, by 
univariate analyses, neither tumor grade, age, gender, adjuvant chemotherapy, nor 
adjuvant CRT were associated with overall survival.  However, tumor stage was 
associated with overall survival (p = 0.003), and nodal status demonstrated a borderline-
significant association (p = 0.08) (Table 4).  In multivariate analysis, only tumor stage 
(T1/2 vs. T3/4) was significantly associated with OS, with HR 5.08 (95% CI 1.95-13.25, 
p < 0.001), and age had borderline-significant association, with HR 1.04 (95% CI 1.00–
1.08, p = 0.06).  Tumor grade, nodal status, adjuvant CRT, and adjuvant chemotherapy 
were not significant independent predictors of survival. 
 
 
DISCUSSION 
 In the current study, tumor stage and age were associated with OS, and the MST 
was not reached for T1/T2 tumors.  A similar association between tumor stage and OS 
has been reported in previous series, including recent reports from M.D. Anderson 
Cancer Center9 and Johns Hopkins Hospital13 that showed inferior OS for T3 and T4 AC 
tumors compared to T1 and T2 tumors.  The median survival seen in the current series 
compares favorably with that found at Hopkins (50 versus 36 months).  Additionally, 5-
year survival rates were similar for lymph node negative (60%) and T1/T2 tumors (65%) 
to those seen in the group reported by M.D. Anderson.  The significant association 
between age and OS differs from the findings of other investigators, including Krishnan 
et al. and Yeh et al., who found that advanced age was not associated with inferior 
survival after PD for AC.9,14  Conclusions regarding the influence of age on OS for AC 
are limited due to the relatively small numbers of patients in these series.  Lymph node 
involvement, which has been shown to be associated with OS in multiple series,1,3,5,15,16 
was a borderline-significant predictor of OS in the current series, with median survival 
time of 84 months for N0 patients versus 17 months for N1 patients.  In our experience, 
lymph node-negative AC patients had lower rates of recurrence and better overall 
survival than patients with nodal involvement.  The current study is limited by its 
retrospective design, with non-randomized treatment allocation, as well as the relatively 
small number of patients treated for this uncommon cancer diagnosis.  It is possible that a 
significant association between nodal status and OS would be revealed with a larger 
population of AC patients. 
 The role of adjuvant CRT in the management of AC is not clear.  In the present 
study, adjuvant CRT did not influence OS.  Interpretation of the observed lack of effect 
of CRT on OS is limited by the small number of patients in this study; less than 50% of 
patients in our series received any adjuvant therapy.  The EORTC prospective trial of 
CRT for periampullary cancers included 92 patients with AC.  In this EORTC trial, 
which comprised the only prospective, randomized data for CRT in AC, CRT did not 
improve OS, with 2 year survival rate of 70% versus 64% with and without CRT, 
respectively.8  Similarly, Zhou and colleagues, in their 2009 report of 111 AC patients 
treated at the Johns Hopkins Hospital, also observed no clinical benefit from CRT.13  A 
recent report by Krishnan et al., from MD Anderson, observed that CRT improved 
survival for AC patients with T3/T4 tumors, but not for patients with involved lymph 
nodes.9  On the other hand, adjuvant CRT has been reported by other authors to improve 
survival for AC patients with positive lymph nodes.5,17  Future studies that include a 
larger number of patients may provide further insight into which subsets of AC patients 
will benefit from adjuvant CRT. 
 Previous reports have focused on the identification of high-risk factors that 
predict for higher rates of recurrence, using either models of multiple pathologic factors 
or lymph node-based parameters, such as number of positive nodes and lymph node ratio 
10,15,16
.  Given the influence of lymph node status on rates of recurrence and survival after 
PD for AC, it seems reasonable to consider closely these lymph node parameters when 
evaluating prognosis.  Recent data have demonstrated that primary tumor stage and nodal 
status are correlated in AC, with increased risk of nodal metastasis for T3/4 (71.1-77.3%) 
versus T1/2 (28.0-50.9%) tumors.18  It is unclear whether these prognostic approaches 
may be used as the basis for decisions regarding adjuvant CRT for AC patients.  
Although the current analysis suggests that tumor stage, age, and lymph node 
involvement are associated with overall survival, the addition of adjuvant CRT after PD 
did not improve survival.  Since they are associated with inferior survival after PD, these 
adverse factors should be considered when developing novel strategies for adjuvant 
therapy for AC patients.   
 In conclusion, only primary tumor stage, and not nodal status or the use of 
adjuvant CRT, was associated with OS after PC for AC.  Patients with advanced primary 
tumor stage should be considered for clinical trials of adjuvant therapy with novel 
compounds and optimized RT strategies, while observation following surgical resection 
may be considered for patients with T1/2 and node-negative AC. 
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Figure Legends 
Figure 1. Kaplan-Meier plot of overall survival (solid line) for all ampullary carcinoma 
patients (n=61) after pancreaticoduodenectomy, with 95% confidence intervals (dashed 
line)..  
Figure 2. Kaplan-Meier plot of overall survival for ampullary carcinoma patients after 
pancreaticoduodenectomy by primary tumor stage, comparing T1/T2 tumors (solid line, 
n=33) to T3/T4 tumors (dashed line, n=28) (p = 0.003). 
Figure 3. Kaplan-Meier plot of overall survival for ampullary carcinoma patients after 
pancreaticoduodenectomy by nodal status, comparing lymph node-negative (N0, solid 
line, n=20) to lymph node-positive (N1, dashed line, n=41) (p = 0.081). 
 
 
 
 
 
  
 
 
TABLES 
 
Primary Tumor (T) 
TX: Primary tumor cannot be assessed 
T0: No evidence of primary tumor 
Tis: Carcinoma in Situ 
T1: Tumor confined in ampulla of Vater or 
sphincter of Oddi 
T2: Tumor involves duodenal wall 
T3: Tumor invades pancreas 
T4: Tumor invades peripancreatic soft tissue 
or other organs 
Regional Lymph Nodes (N) 
NX: Regional lymph nodes cannot be 
assessed  
N0: No regional lymph node metastasis  
N1: Regional lymph node metastasis 
Distant Metastasis (M) 
MX: Distant metastasis cannot be assessed 
M0: No distant metastasis 
M1: Distant Metastasis 
Table 1.  Pathologic staging system for ampullary carcinoma, according to American Joint 
Committee on Cancer (AJCC) Version 7.  Used with the permission of the AJCC, Chicago, IL.  
The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010), 
published by Springer Science+Business Media. 
 
Stage Grouping 
Stage T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1-3 N1 M0 
III T4 Any N M0 
IV Any T Any N M1 
Table 2. Stage grouping system for ampullary carcinoma, according to American Joint 
Committee on Cancer (AJCC) Version 7.  Used with the permission of the AJCC, Chicago, IL.  
The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010), 
published by Springer Science+Business Media. 
 
 
 
 
 
  
 
 
Factor Value 
Age  
       Mean (Interquartile Range) 
 
70 years (54, 76) 
Grade [N(%)] 
       Well-differentiated 
       Moderately-differentiated 
       Poorly-differentiated 
       Unknown 
 
6     (10%) 
36   (59%) 
16   (26%) 
3     (5%) 
Stage [N(%)] 
       I 
       II 
       III 
       IV 
 
19   (31%) 
29   (48%) 
12   (20%) 
1     (2%) 
Nodal Status [N(%)] 
      N0 
      N1 
 
20   (33%) 
41   (67%) 
Surgical Margin Status [N(%)] 
      R0 (negative) 
      R1 (microscopic positive) 
      R2 (macroscopic positive) 
 
58   (95%) 
3     (5%) 
0     (0%) 
Adjuvant Chemoradiotherapy [N(%)] 
      Yes 
      No 
      Unknown 
 
16   (26%) 
36   (59%) 
9     (15%) 
Adjuvant Chemotherapy [N(%)] 
     Yes 
     No 
     Unknown 
 
25   (41%) 
28   (46%) 
8     (13%) 
Table 3. Age, tumor, and adjuvant therapy information for 61 ampullary carcinoma 
patients who were treated with pancreaticoduodenectomy. 
 Variable 
Hazard Ratio  
(95% Confidence Interval) 
P value 
Tumor Stage  
(T1/2 vs. T3/4) 
4.05 (1.6-10.1) 0.003 
Grade 
(Well/Moderate vs. Poor) 
1.8 (0.8-4.5) 0.183 
Age 1.0 (1.0-1.1) 0.225 
Nodal Status 
(Negative vs. Positive) 
2.2 (0.9-5.4) 0.081 
Adjuvant Chemoradiotherapy 
(Yes vs. No) 
1.2 (0.5-3.0) 0.713 
Adjuvant Chemotherapy 
Alone 
(Yes vs. No) 
0.9 (0.4-2.0) 0.741 
Gender 
(Male vs. Female) 
0.6 (0.2-1.4) 0.235 
Table 4.  Univariate Cox proportional models of overall survival.  
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Figure 1. Kaplan-Meier plot of overall survival (solid line) for all ampullary carcinoma 
patients (n=61) after pancreaticoduodenectomy, with 95% confidence intervals (dashed 
line)..  
  
 Figure 2. Kaplan-Meier plot of overall survival for ampullary carcinoma patients after 
pancreaticoduodenectomy by primary tumor stage, comparing T1/T2 tumors (solid line, 
n=33) to T3/T4 tumors (dashed line, n=28) (p = 0.003). 
. 
 
  
 
Figure 3. Kaplan-Meier plot of overall survival for ampullary carcinoma patients after 
pancreaticoduodenectomy by nodal status, comparing lymph node-negative (N0, solid 
line, n=20) to lymph node-positive (N1, dashed line, n=41) (p = 0.081). 
 
 
 
